
    
      Upon determination of eligibility, patients will be receive:

        -  Topotecan + Carboplatin

      In order to determine the most appropriate dosing regimen to progress into future phase II
      trials, two different dosing schedules of topotecan and carboplatin will be utilized (ARM I
      and ARM II). Patients will be accrued to both treatment arms simultaneously.
    
  